tp odn Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    GE Healthcare tp odn
    Tp Odn, supplied by GE Healthcare, used in various techniques. Bioz Stars score: 90/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tp odn/product/GE Healthcare
    Average 90 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    tp odn - by Bioz Stars, 2020-08
    90/100 stars
      Buy from Supplier

    90
    GE Healthcare tp odn stock solution
    ( a ) A stably transfected vector in HeLa cells expresses two luciferase genes. Firefly luciferase is expressed constitutively, whereas expression of the renilla luciferase gene is under the control of miR-15b as part of the RNA-induced silencing complex (RISC). In the presence of an anti-miR-15b oligonucleotide (TP <t>ODN</t> in this figure), the RISC dissociates from the renilla gene. This leads to an increase in renilla luciferase activity. Comparison of the activity of renilla luciferase to the unregulated firefly luciferase yields an indication of the activity of an oligonucleotide as an anti-miR-15b oligonucleotide. ( a ) Adapted from the Integrated DNA Technologies Inc. (Coralville, IA, USA) website. The stably transfected HeLa cell line and assay protocols were developed by miRagen Therapeutics, Inc. ( b ) Lipid <t>transfection</t> using DharmaFECT 1 (Dharmacon). ( c ) Passive transfection using TP ODNs. Positive and negative controls were purchased from Dharmacon: miRIDIAN Hairpin Inhibitor (IH-300587-07) and miRIDIAN Hairpin Inhibitor Negative Control #1 (IN-001005-01).
    Tp Odn Stock Solution, supplied by GE Healthcare, used in various techniques. Bioz Stars score: 90/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tp odn stock solution/product/GE Healthcare
    Average 90 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    tp odn stock solution - by Bioz Stars, 2020-08
    90/100 stars
      Buy from Supplier

    Image Search Results


    ( a ) A stably transfected vector in HeLa cells expresses two luciferase genes. Firefly luciferase is expressed constitutively, whereas expression of the renilla luciferase gene is under the control of miR-15b as part of the RNA-induced silencing complex (RISC). In the presence of an anti-miR-15b oligonucleotide (TP ODN in this figure), the RISC dissociates from the renilla gene. This leads to an increase in renilla luciferase activity. Comparison of the activity of renilla luciferase to the unregulated firefly luciferase yields an indication of the activity of an oligonucleotide as an anti-miR-15b oligonucleotide. ( a ) Adapted from the Integrated DNA Technologies Inc. (Coralville, IA, USA) website. The stably transfected HeLa cell line and assay protocols were developed by miRagen Therapeutics, Inc. ( b ) Lipid transfection using DharmaFECT 1 (Dharmacon). ( c ) Passive transfection using TP ODNs. Positive and negative controls were purchased from Dharmacon: miRIDIAN Hairpin Inhibitor (IH-300587-07) and miRIDIAN Hairpin Inhibitor Negative Control #1 (IN-001005-01).

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Peptide-substituted oligonucleotide synthesis and non-toxic, passive cell delivery

    doi: 10.1038/sigtrans.2016.19

    Figure Lengend Snippet: ( a ) A stably transfected vector in HeLa cells expresses two luciferase genes. Firefly luciferase is expressed constitutively, whereas expression of the renilla luciferase gene is under the control of miR-15b as part of the RNA-induced silencing complex (RISC). In the presence of an anti-miR-15b oligonucleotide (TP ODN in this figure), the RISC dissociates from the renilla gene. This leads to an increase in renilla luciferase activity. Comparison of the activity of renilla luciferase to the unregulated firefly luciferase yields an indication of the activity of an oligonucleotide as an anti-miR-15b oligonucleotide. ( a ) Adapted from the Integrated DNA Technologies Inc. (Coralville, IA, USA) website. The stably transfected HeLa cell line and assay protocols were developed by miRagen Therapeutics, Inc. ( b ) Lipid transfection using DharmaFECT 1 (Dharmacon). ( c ) Passive transfection using TP ODNs. Positive and negative controls were purchased from Dharmacon: miRIDIAN Hairpin Inhibitor (IH-300587-07) and miRIDIAN Hairpin Inhibitor Negative Control #1 (IN-001005-01).

    Article Snippet: Passive transfection as in a dual-luciferase assay A TP ODN stock solution in water (Hyclone Cell Molecular biology Grade, Invitrogen) was added to 375 μl reduced serum without antibiotic medium (2% FBS, 1× GlutaMAX, 1× non-essential amino acids and 1× sodium pyruvate) so as to obtain a final concentration of 1 μM TP ODN.

    Techniques: Stable Transfection, Transfection, Plasmid Preparation, Luciferase, Expressing, Activity Assay, IA, Negative Control

    The effect of 1 μg ml −1 brefeldin A (BFA), 100 μM chloroquine (CQ) and 100 μM histidine (His) on endosomal release of a TP ODN (FL-4PA). Note that the suggested concentration of BFA is 10 μg ml −1 for endosomal release. In the research reported here, this concentration caused significant toxicity even after a short treatment. Thus, a lower and less toxic 1 μg ml −1 concentration was used for this experiment. Passive transfection was performed using 3 μM TP ODN FL-4PA for 24 h followed by washing. Cells were then incubated with BFA, CQ and His, respectively. Three-dimensional microscopy was taken at 0.5 μm per step for 30 steps. Fl-4PA: 5′-FL-T PepA GTAAAC PepA CATGA PepA TGTGCTGCT PepA A-3′. PepA, AcHN-Lys(N 3 )-Lys-Lys-Arg-Gly-NH 2 .

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Peptide-substituted oligonucleotide synthesis and non-toxic, passive cell delivery

    doi: 10.1038/sigtrans.2016.19

    Figure Lengend Snippet: The effect of 1 μg ml −1 brefeldin A (BFA), 100 μM chloroquine (CQ) and 100 μM histidine (His) on endosomal release of a TP ODN (FL-4PA). Note that the suggested concentration of BFA is 10 μg ml −1 for endosomal release. In the research reported here, this concentration caused significant toxicity even after a short treatment. Thus, a lower and less toxic 1 μg ml −1 concentration was used for this experiment. Passive transfection was performed using 3 μM TP ODN FL-4PA for 24 h followed by washing. Cells were then incubated with BFA, CQ and His, respectively. Three-dimensional microscopy was taken at 0.5 μm per step for 30 steps. Fl-4PA: 5′-FL-T PepA GTAAAC PepA CATGA PepA TGTGCTGCT PepA A-3′. PepA, AcHN-Lys(N 3 )-Lys-Lys-Arg-Gly-NH 2 .

    Article Snippet: Passive transfection as in a dual-luciferase assay A TP ODN stock solution in water (Hyclone Cell Molecular biology Grade, Invitrogen) was added to 375 μl reduced serum without antibiotic medium (2% FBS, 1× GlutaMAX, 1× non-essential amino acids and 1× sodium pyruvate) so as to obtain a final concentration of 1 μM TP ODN.

    Techniques: Concentration Assay, Transfection, Incubation, Microscopy